Drug Profile

Drug: Degludec
Condition: Diabetes Mellitus Type 2
Brand Names: Tresiba
Keywords: Insulin degludec, long-ating insulin anaogues, long acting insulin analogues
BNF Codes: Please select a BNF chapter code to go to the formulary.
060101 - Insulin

Committee Recommendations

Date Committee Name Narrative Traffic Light Status Traffic Light Status
05 April 2017 Prescribing Clinical Network See narrative below from Sep 2016.

The Sep 2016 policy statement has been subject to a minor change and an amended statement is available below.
Blue
07 September 2016 Prescribing Clinical Network The PCN recommends the use of Insulin Degludec (Tresiba®) in type II diabetes in line with the policy statement (217-2016) below. Insulin Degludec (Tresiba®) in type II diabetes will be considered as BLUE (without an information sheet) on the traffic light system

Important - Insulin degludec is available in strengths of 100units/mL and 200units/mL - ensure correct strength is prescribed and dispensed - see MHRA Safety Update (below) for key points and practical information.
Blue

Documents

Type: Document (click to view) Review Date
Policy Statement Degludec for Type 2 diabetes - Policy statement 217-2016 - amended Apr 2017 Degludec for Type 2 diabetes - Policy statement 217-2016 - amended Apr 2017 PDF April 2020
Information Degludec - MHRA drug safety update - April 2013 Degludec - MHRA drug safety update - April 2013 PDF
Information Degludec for Type 2 diabetes - Change in Traffic Light status application - Sep 2016 Degludec for Type 2 diabetes - Change in Traffic Light status application - Sep 2016 PDF

Supplementary documents (organisational specific)

Relevant for the
following organisations:
Document (click to view) Type: Review Date
Surrey Downs CCG SDCCG - Insulin initiation in Type 2 Diabetes Guidelines - Sep 2014 SDCCG - Insulin initiation in Type 2 Diabetes Guidelines - Sep 2014 PDF Guidelines (Local) October 2015